Senator Bernie Sanders, I-Vermont, has claimed his Medicare-for-all plan will cut healthcare spending by $2 trillion, but fact checking shows that's unlikely; CVS' CEO defends its pharmacy benefit manager against claims rebates are driving up drug prices; researchers have found that immigrants have healthcare costs that are half to two-thirds of the costs of people born in the United States.
Senator Bernie Sanders, I-Vermont, has made big claims about the savings Americans will enjoy under his Medicare-for-all plan, but he might be overlooking some facts. The Associated Press fact checked Sanders’ claims and noted that his claim that the plan will cut $2 trillion from the country’s healthcare bill is reliant on a scenario of significantly lower payments to hospitals and doctors for most patients. The reality is that if providers are paid the same under the plan, spending would increase by more than $3 trillion.
The Trump administration has criticized high drug prices and rebates paid to pharmacy benefit managers like Caremark, owned by CVS Health, for driving up prices. Larry Merlo, the CEO of CVS, is defending against the blame, noting that prices of drugs with smaller rebates are actually rising the fastest, reported The Wall Street Journal. Merlo said that 98% of the tens of billions of dollars his company has generated through rebates are passed through to clients—insurers, companies, and groups that pay for medicines.
Researchers from Harvard Medical School and Tufts University have found that immigrants have healthcare costs that are half to two-thirds of the costs of people born in the United States. According to The Hill, immigrants make up 12% of the population, but they account for only 8.6% of the country’s healthcare spending. Undocumented immigrants, who make up 5% of the population, account for only 1.4% of total spending.
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage
April 4th 2025This study examined postdiagnosis breast cancer treatment outcomes for Medicare Advantage vs fee-for-service (FFS) Medicare in Ohio and found no significant differences overall but disparities for Black patients with FFS Medicare.
Read More